David Litoff, MD
Ophthalmology · Denver, CONPI 1720165939
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.3% of the total across 137 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 23 manufacturers reported payments, led by Alcon at 45.6% of the total.
Across 137 payments — averaging $45.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$3K
- Rxsight Inc$950
- Biotissue Holdings Inc.$563
- Glaukos Corporation$550
- Bausch & Lomb Americas Inc.$211
- Johnson & Johnson Surgical Vision, Inc.$206
- plus $927 from 17 others
What the payments were for
- Food & beverage$6,16198%
- Education$170%
- Entertainment$881%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 66 | $2,860 |
| Rxsight Inc | 6 | $950 |
| Biotissue Holdings Inc. | 16 | $563 |
| Glaukos Corporation | 6 | $550 |
| Bausch & Lomb Americas Inc. | 7 | $211 |
| Johnson & Johnson Surgical Vision, Inc. | 4 | $206 |
| Novartis | 5 | $178 |
| AbbVie(2 entities) | 6 | $119 |
| Dompe US, Inc. | 1 | $114 |
| Sun Pharmaceutical Industries Inc. | 4 | $108 |
| Optos, Inc. | 1 | $88 |
| Mallinckrodt Hospital Products Inc. | 2 | $49 |
| Carl Zeiss Meditec, Inc. | 1 | $48 |
| Harrow Eye, LLC | 2 | $43 |
| Quidel Corporation | 1 | $32 |
| Tearlab Corp | 2 | $31 |
| Thea Pharma Inc. | 1 | $22 |
| Aerie Pharmaceuticals, Inc. | 1 | $20 |
| Ocular Therapeutix, Inc. | 1 | $16 |
| Staar Surgical Company | 1 | $16 |
| Amgen | 1 | $15 |
| Oyster Point Pharma, Inc. | 1 | $15 |
| Rayner Intraocular Lenses Limited | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RXSIGHT CONTACT LENS$684
- RXSIGHT INJECTOR CARTRIDGE$684
- RXSIGHT INJECTOR HANDPIECE$684
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$684
- Clareon$664
- LIGHT ADJUSTABLE LENS (LAL)$571
- iStent Trabecular Micro-Bypass System Model iS3$159
- iDoseTR$143
- ARGOS$141
- AcrySof IQ PanOptix UV IOL$136
- PanOptix$119
- Prokera$116
- AmnioGraft$116
- LenSx$116
- Oxervate$114
- RXSIGHT LIGHT ADJUSTABLE LENS (RXLAL)$113
- AcrySof$107
- BEOVU$106
How this compares
$6,266 in reported general payments places this provider in the 85th percentile of 262 ophthalmology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxervateCenegermin-Bkbj | 23 | $655,134 |
| XiidraLifitegrast | 22 | $28,375 |
| RestasisCyclosporine | 13 | $18,295 |
| LumiganBimatoprost | 36 | $17,771 |
| Prednisolone Acetate | 221 | $12,059 |
| Diclofenac Sodium | 219 | $2,449 |
| Latanoprost | 212 | $2,270 |
| Ofloxacin | 212 | $2,255 |
| Loteprednol Etabonate | 15 | $1,932 |
| Travoprost | 14 | $1,734 |
| Timolol Maleate | 44 | $1,340 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 37 | $661 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 35 | $411 |
| Dorzolamide Hcl | 20 | $343 |
| Brimonidine Tartrate | 22 | $97 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Dompe US, Inc.Oxervate | $114 | $655,13423 claims |
| AbbVieRestasis, Lumigan | $119 | $36,06549 claims |
| Bausch & Lomb Americas Inc.Xiidra | $211 | $28,37522 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 262 ophthalmology providers in Colorado.
Other ophthalmology in Denver
- Mark DaceyDenver$370K
- Cristos IfantidesDenver$343K
- Jack ZamoraDenver$172K
- Eva KimDenver$95K
- Michael JansenDenver$95K
- Kingsley OkaforDenver$62K
- Curtis HagedornDenver$25K
- Michael SolomonDenver$12K
- Peter HovlandDenver$10K
- Matthew KrugerDenver$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.